Exclusive: After Covid pivot, biotech nabs funds to be first in the clinic with a non-hormonal contraceptive for men
The goal was to create a non-hormonal contraceptive that women could take to prevent pregnancy and potentially STIs, but the Covid-19 pandemic caused YourChoice Therapeutics to change course and eventually focus most efforts on a non-hormonal pill for men.
With Series A funding and a pre-IND meeting with the FDA under its belt, the biotech expects to be the first company to enter the clinic with an investigational non-hormonal contraceptive for sperm-producers, with the goal of limiting sperm counts to infertile levels. A healthy volunteer study in the US, if greenlit by the agency, will begin in the first half of next year, CEO Akash Bakshi tells Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.